Basing on the results of some phase III clinical trials, the Food and Drug Administration (FDA) has approved PD-1/PD-L1 inhibitors to be used in first- or second-line treatment of patients with advanced NSCLC [4]. Here, PDCD1 is linked to non-small cell lung carcinoma.